Noma M.,Breast and Transplantation Surgery |
Ohara M.,Breast and Transplantation Surgery |
Imaoka Y.,Breast and Transplantation Surgery |
Mashima H.,Breast and Transplantation Surgery |
And 14 more authors.
Japanese Journal of Cancer and Chemotherapy | Year: 2014
We report a case of a 64-year-old woman with Stage IV breast cancer who responded well to chemotherapy containing bevacizumab. She noticed a left breast tumor with acute progression and was diagnosed as having Stage IV, estrogen receptor (ER) (-), progesterone receptor (PgR) (-), human epidermal growth factor receptor 2 (HER2) (-) breast cancer (T4cN3cM1 [lymph nodes]). She received 5 courses of adriamycin (60 mg/m2) plus cyclophosphamide (600mg/m2) (AC therapy) and 4 courses of weekly paclitaxel (PTX 90 mg/m2) plus bevacizumab (AVA 10 mg/m2) as systemic therapy. Computed tomography (CT) and magnetic resonance imaging (MRI) revealed a complete response (CR). After local resection of the breast tumor and radiation to the breast and regional lymph nodes, capecitabine therapy was initiated. Currently, at 5 months after surgery, no new lesion has been detected.